SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-512651"
 

Search: onr:"swepub:oai:DiVA.org:uu-512651" > Effects of Dapaglif...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Effects of Dapagliflozin in Heart Failure with Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease : An Analysis of DAPA-HF.

Dewan, Pooja (author)
Docherty, Kieran F. (author)
Bengtsson, Olof (author)
show more...
de Boer, Rudolf A. (author)
Desai, Akshay S. (author)
Drozdz, Jaroslaw (author)
Hawkins, Nathaniel M. (author)
Inzucchi, Silvio E. (author)
Kitakaze, Masafumi (author)
Kober, Lars (author)
Kosiborod, Mikail N. (author)
Langkilde, Anna Maria (author)
Lindholm, Daniel (author)
Martinez, Felipe A. (author)
Merkely, Bela (author)
Petrie, Mark C. (author)
Ponikowski, Piotr (author)
Sabatine, Marc S. (author)
Schou, Morten (author)
Sjostrand, Mikaela (author)
Solomon, Scott D. (author)
Verma, Subodh (author)
Jhund, Pardeep S. (author)
McMurray, John J. V. (author)
show less...
2021-01-18
2021
English.
In: European journal of heart failure. - : Wiley. - 1388-9842 .- 1879-0844. ; 23:4, s. 632-643
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • AIMS: Chronic obstructive pulmonary disease (COPD) is an important comorbidity in heart failure (HF) with reduced ejection fraction (HFrEF), associated with worse outcomes and often suboptimal treatment because of under-prescription of beta-blockers. Consequently, additional effective therapies are especially relevant in patients with COPD. The aim of this study was to examine outcomes related to COPD in a post hoc analysis of the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial. METHODS AND RESULTS: We examined whether the effects of dapagliflozin in DAPA-HF were modified by COPD status. The primary outcome was the composite of an episode of worsening HF or cardiovascular death. Overall, 585 (12.3%) of the 4744 patients randomized had a history of COPD. Patients with COPD were more likely to be older men with a history of smoking, worse renal function, and higher baseline N-terminal pro B-type natriuretic peptide, and less likely to be treated with a beta-blocker or mineralocorticoid receptor antagonist. The incidence of the primary outcome was higher in patients with COPD than in those without [18.9 (95% confidence interval 16.0-22.2) vs. 13.0 (12.1-14.0) per 100 person-years; hazard ratio (HR) for COPD vs. no COPD 1.44 (1.21-1.72); P $<$ 0.001]. The effect of dapagliflozin, compared with placebo, on the primary outcome, was consistent in patients with [HR 0.67 (95% confidence interval 0.48-0.93)] and without COPD [0.76 (0.65-0.87); interaction P-value 0.47]. CONCLUSIONS: In DAPA-HF, one in eight patients with HFrEF had concomitant COPD. Participants with COPD had a higher risk of the primary outcome. The benefit of dapagliflozin on all pre-specified outcomes was consistent in patients with and without COPD. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov ID NCT03036124.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Keyword

*Heart Failure/complications/drug therapy/epidemiology
*Pulmonary Disease
Chronic Obstructive/complications/drug therapy/epidemiology
Aged
Benzhydryl Compounds
Chronic obstructive pulmonary disease
Dapagliflozin
Glucosides/therapeutic use
Heart failure
Humans
Male
Stroke Volume

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view